Sinus implant

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Retrieved on: 
Thursday, May 20, 2021

The Contour CE approval expands the portfolio of PROPEL products available for commercialization inclusive of PROPEL and PROPEL Mini.

Key Points: 
  • The Contour CE approval expands the portfolio of PROPEL products available for commercialization inclusive of PROPEL and PROPEL Mini.
  • PROPEL Contour is specifically designed to maintain patency and reduce inflammation, and conform to the sinus ostia (openings) by focusing mechanical support and steroid delivery where it is needed to optimize sinus surgery outcomes.
  • It is the third localized drug delivery implant, completing the PROPEL family of drug-eluting, bioabsorable implants now available to ENT specialists in select EU countries.\nPROPEL Contour features an innovative hourglass shape, specifically designed for placement in the frontal sinuses (between the eyebrows) following sinus surgery for chronic rhinosinusitis patients.
  • A Corticosteroid-Eluting Sinus Implant Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis: A UK-Based Cost-Effectiveness Analysis.

EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation

Retrieved on: 
Thursday, April 29, 2021

EXPAND is a prospective, randomized, single-blind, intra-patient controlled, post-market clinical trial enrolling approximately 80 patients in the United States.

Key Points: 
  • EXPAND is a prospective, randomized, single-blind, intra-patient controlled, post-market clinical trial enrolling approximately 80 patients in the United States.
  • The EXPAND study\xe2\x80\x99s primary objective is to evaluate the efficacy of the Company\xe2\x80\x99s PROPEL\xc2\xae Contour (mometasone furoate) sinus implant when placed in the frontal sinus ostium following in-office balloon dilation in patients with chronic rhinosinusitis (CRS) as compared to balloon sinus dilation alone.
  • There are approximately 150,000 balloon sinus dilation procedures performed annually in the United States with a substantial number of these procedures treating the frontal sinus ostia in ENT surgeons\xe2\x80\x99 offices.
  • Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection.

Intersect ENT to Report First Quarter 2021 Financial Results

Retrieved on: 
Tuesday, April 20, 2021

b'Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (\xe2\x80\x9cENT\xe2\x80\x9d) medical technology leader dedicated to transforming patient care, today announced that it will release first quarter 2021 financial results on Tuesday, May 4, 2021.

Key Points: 
  • b'Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (\xe2\x80\x9cENT\xe2\x80\x9d) medical technology leader dedicated to transforming patient care, today announced that it will release first quarter 2021 financial results on Tuesday, May 4, 2021.
  • To access the live conference call via phone, dial 844-850-0548 and ask to join the Intersect ENT call.
  • The Company\xe2\x80\x99s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease.
  • For more information about PROPEL\xc2\xae (mometasone furoate) sinus implants and SINUVA\xc2\xae (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com .\nIntersect ENT\xc2\xae, PROPEL\xc2\xae and SINUVA\xc2\xae are registered trademarks of Intersect ENT, Inc.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005271/en/\n'

Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Wednesday, March 10, 2021

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference.

Key Points: 
  • Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference.
  • Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care.
  • For more information about PROPEL (mometasone furoate) sinus implants and SINUVA (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com .
  • Intersect ENT, PROPEL and SINUVA, are registered trademarks of Intersect ENT, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005176/en/

CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication

Retrieved on: 
Monday, March 8, 2021

In January 2021, CMS created separate and distinct codes for Intersect ENTs two bioabsorbable implant product lines PROPEL (S1091) and SINUVA (J7402).

Key Points: 
  • In January 2021, CMS created separate and distinct codes for Intersect ENTs two bioabsorbable implant product lines PROPEL (S1091) and SINUVA (J7402).
  • CMS has now attached an ASP to J7402, mometasone furoate sinus implant, (sinuva), 10 micrograms.
  • We are pleased that CMS consolidated SINUVA coverage to a single code and published a SINUVA ASP.
  • For more information about PROPEL (mometasone furoate) sinus implants and SINUVA (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com .

Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant

Retrieved on: 
Thursday, February 11, 2021

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (SDS) packaged with the companys PROPEL Mini (mometasone furoate) Sinus Implant.

Key Points: 
  • Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (SDS) packaged with the companys PROPEL Mini (mometasone furoate) Sinus Implant.
  • It is specifically engineered for precise, consistent and easy delivery of the PROPEL Mini implant into the ethmoid sinus for maximum tissue apposition.
  • The original curved delivery system will continue to be available with the PROPEL Mini sinus implant, offering physicians a suite of options when using PROPEL Mini following sinus surgery.
  • Intersect ENT is pleased to provide our physicians with a complete package of PROPEL Mini and the Straight Delivery System, commented Thomas A.

Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant

Retrieved on: 
Tuesday, January 19, 2021

The approval of this new application establishes a separate code for PROPEL, S1091 "Stent, non-coronary, temporary, with delivery system (propel), as well as updates the current SINUVA J-Code to, J7402 Mometasone furoate sinus implant, (sinuva), 10 micrograms.

Key Points: 
  • The approval of this new application establishes a separate code for PROPEL, S1091 "Stent, non-coronary, temporary, with delivery system (propel), as well as updates the current SINUVA J-Code to, J7402 Mometasone furoate sinus implant, (sinuva), 10 micrograms.
  • CMS will discontinue the original shared Level II HCPCS code J7401 "Mometasone furoate sinus implant, 10 micrograms.
  • For more information about PROPEL (mometasone furoate) sinus implants and SINUVA (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com .
  • The PRROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients >18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia.

Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant

Retrieved on: 
Thursday, September 10, 2020

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today announced that it has executed a pharmacy services agreement with AllianceRx Walgreens Prime for national specialty pharmacy distribution of the Companys SINUVA (mometasone furoate) Sinus Implant.

Key Points: 
  • Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today announced that it has executed a pharmacy services agreement with AllianceRx Walgreens Prime for national specialty pharmacy distribution of the Companys SINUVA (mometasone furoate) Sinus Implant.
  • The agreement will facilitate broader physician and patient access to SINUVA by using the expertise and established specialty pharmacy infrastructure of AllianceRx Walgreens Prime to dispense SINUVA through either a patients medical or pharmacy insurance benefit.
  • SINUVA is a non-surgical, corticosteroid-eluting implant for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery.
  • AllianceRx Walgreens Prime is pleased to have the opportunity to work collaboratively with Intersect ENT in helping to expand the availability of SINUVA to ENT practices and their patients, says Tracey James, Vice President of Pharmacy Services, at AllianceRx Walgreens Prime.

New Treatment for Sinus Graft Infections

Retrieved on: 
Thursday, July 9, 2020

Some methods for treatment have been introduced, but they are focused on endoscopic sinus surgery, in which infected sinus tissues and the implant are removed.

Key Points: 
  • Some methods for treatment have been introduced, but they are focused on endoscopic sinus surgery, in which infected sinus tissues and the implant are removed.
  • In a new study in the Journal of Oral Implantology, clinicians detailed and evaluated a new intra-oral treatment for sinusitis after maxillary sinus augmentation for ensuring long-term implant use.
  • Because of the positive outcomes, the authors highlight that sinusitis after sinus augmentation surgery in these cases resulted from an infection caused by the sinus graft itself and not a problem of the sinus membrane.
  • Full text of the article "Intra-Oral Approach for Sinus Graft Infection following Lateral Sinus Floor Augmentation with Simultaneous Implant Placement: A Clinical Case Series," Journal of Oral Implantology, is available at https://doi.org/10.1563/aaid-joi-D-18-00296 .

Intersect ENT Announces Independent Analysis in UK Confirming Cost Effectiveness of PROPEL® Steroid Releasing Sinus Implant Following Sinus Surgery for Chronic Sinusitis

Retrieved on: 
Tuesday, June 23, 2020

While the cost of initial treatment with PROPEL was greater, a reduction in the number of post-operative complications resulted in an overall cost savings.

Key Points: 
  • While the cost of initial treatment with PROPEL was greater, a reduction in the number of post-operative complications resulted in an overall cost savings.
  • PROPEL offers patients with chronic rhinosinusitis a safe and effective option that reduces the likelihood of unpleasant complications, thereby decreasing the need for post-operative interventions.
  • Intersect ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the US and other countries.
  • The PROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients 18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia.